Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Prezista
PREZISTA 100 mg/ml oral suspension · Abschnitt 4.5 · PDF-Seite 18–19
HOS-116385 · Präparat HOS-094447
18
ANTIMYCOBACTERIALS
Rifampicin Not studied. Rifapentine and rifampicin The combination of rifapentine and
Rifapentine are strong CYP3A inducers and have boosted PREZISTA is not
been shown to cause profound decreases recommended.
in concentrations of other protease
inhibitors, which can result in virological The combination of rifampicin and
failure and resistance development boosted PREZISTA is
(CYP450 enzyme induction). During contraindicated (see section 4.3).
attempts to overcome the decreased
exposure by increasing the dose of other
protease inhibitors with low dose
ritonavir, a high frequency of liver
reactions was seen with rifampicin.
Rifabutin rifabutin AUC** ↑ 55% A dosage reduction of rifabutin by
150 mg once every other rifabutin Cmin** ↑ ND 75% of the usual dose of
day rifabutin Cmax** ↔ 300 mg/day (i.e. rifabutin 150 mg
darunavir AUC ↑ 53% once every other day) and
darunavir Cmin ↑ 68% increased monitoring for rifabutin
related adverse events is warranted
darunavir Cmax ↑ 39%
** in patients receiving the
sum of active moieties of rifabutin (parent
combination with PREZISTA
drug + 25-O-desacetyl metabolite)
co-administered with ritonavir. In
case of safety issues, a further
The interaction trial showed a
increase of the dosing interval for
comparable daily systemic exposure for
rifabutin and/or monitoring of
rifabutin between treatment at 300 mg
rifabutin levels should be
once daily alone and 150 mg once every
considered.
other day in combination with
Consideration should be given to
PREZISTA/ritonavir (600/100 mg twice
official guidance on the
daily) with an about 10-fold increase in
appropriate treatment of
the daily exposure to the active
tuberculosis in HIV infected
metabolite 25-O-desacetylrifabutin.
patients.
Furthermore, AUC of the sum of active
Based upon the safety profile of
moieties of rifabutin (parent drug
PREZISTA/ritonavir, the increase
+ 25-O-desacetyl metabolite) was
in darunavir exposure in the
increased 1.6-fold, while Cmax remained presence of rifabutin does not
comparable. warrant a dose adjustment for
Data on comparison with a 150 mg once PREZISTA/ritonavir.
daily reference dose is lacking. Based on pharmacokinetic
modeling, this dosage reduction of
(Rifabutin is an inducer and substrate of 75% is also applicable if patients
CYP3A.) An increase of systemic receive rifabutin at doses other
exposure to darunavir was observed when than 300 mg/day.
PREZISTA co-administered with 100 mg
ritonavir was co-administered with Co-administration of PREZISTA
rifabutin (150 mg once every other day). co-administered with cobicistat
and rifabutin is not recommended.
ANTINEOPLASTICS
Dasatinib Not studied. Boosted PREZISTA is Concentrations of these medicinal
Nilotinib expected to increase these antineoplastic products may be increased when
Vinblastine plasma concentrations. co-administered with boosted
Vincristine (CYP3A inhibition) PREZISTA resulting in the
potential for increased adverse
events usually associated with
these agents.
Caution should be exercised when
combining one of these
antineoplastic agents with boosted
PREZISTA.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dasatinib (HOS-086217) protease (HOS-085623) rifabutin (HOS-086262) vinblastine (HOS-086220) cobicistat (HOS-088111) vincristine (HOS-086219) rifapentine (HOS-116386) ritonavir (HOS-084521) nilotinib (HOS-086218)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 80d9982d7333f238a9b42ff2871813e3ef61b0aafc430c83e6b17352f5e98202 · Zeichen 44997–51632 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 75 mg film-coated tablets PREZISTA 150 mg film-coated tablets PREZISTA 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 59–60
HOS-116524 · Präparat HOS-094447
59
ANTIGOUT MEDICINES
Colchicine Not studied. Concomitant use of A reduction in colchicine dosage
colchicine and darunavir co-administered or an interruption of colchicine
with low dose ritonavir may increase the treatment is recommended in
exposure to colchicine. patients with normal renal or
(CYP3A and/ or P-gp inhibition) hepatic function if treatment with
PREZISTA co-administered with
low dose ritonavir is required. For
patients with renal or hepatic
impairment colchicine with
PREZISTA co-administered with
low dose ritonavir is
contraindicated (see sections 4.3
and 4.4).
ANTIMALARIALS
Artemether/Lumefantrine artemether AUC ↓ 16% The combination of PREZISTA
80/480 mg, 6 doses at 0, artemether Cmin ↔ and artemether/lumefantrine can
8, 24, 36, 48, and artemether Cmax ↓ 18% be used without dose adjustments;
60 hours dihydroartemisinin AUC ↓ 18% however, due to the increase in
dihydroartemisinin Cmin ↔ lumefantrine exposure, the
dihydroartemisinin Cmax ↓ 18% combination should be used with
lumefantrine AUC ↑ 175% caution.
lumefantrine Cmin ↑ 126%
lumefantrine Cmax ↑ 65%
darunavir AUC ↔
darunavir Cmin ↓ 13%
darunavir Cmax ↔
ANTIMYCOBACTERIALS
Rifampicin Not studied. Rifapentine and rifampicin The combination of rifapentine and
Rifapentine are strong CYP3A inducers and have PREZISTA with concomitant low
been shown to cause profound decreases dose ritonavir is not recommended.
in concentrations of other protease
inhibitors, which can result in virological The combination of rifampicin and
failure and resistance development PREZISTA with concomitant low
(CYP450 enzyme induction). During dose ritonavir is contraindicated
attempts to overcome the decreased (see section 4.3).
exposure by increasing the dose of other
protease inhibitors with low dose
ritonavir, a high frequency of liver
reactions was seen with rifampicin.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lumefantrine (HOS-114826) artemether (HOS-116383) protease (HOS-085623) colchicine (HOS-086147) rifapentine (HOS-116386) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 74158b50c5b99095b0e72f07cfddcb7308a227dde01097c23cb4f0a091942901 · Zeichen 33301–36423 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 400 mg film-coated tablets PREZISTA 800 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 100–101
HOS-116615 · Präparat HOS-094447
100
ANTIMYCOBACTERIALS
Rifampicin Not studied. Rifapentine and rifampicin The combination of rifapentine and
Rifapentine are strong CYP3A inducers and have boosted PREZISTA is not
been shown to cause profound decreases recommended.
in concentrations of other protease
inhibitors, which can result in virological The combination of rifampicin and
failure and resistance development boosted PREZISTA is
(CYP450 enzyme induction). During contraindicated (see section 4.3).
attempts to overcome the decreased
exposure by increasing the dose of other
protease inhibitors with low dose
ritonavir, a high frequency of liver
reactions was seen with rifampicin.
Rifabutin rifabutin AUC** ↑ 55% A dosage reduction of rifabutin by
150 mg once every other rifabutin Cmin** ↑ ND 75% of the usual dose of
day rifabutin Cmax** ↔ 300 mg/day (i.e. rifabutin 150 mg
darunavir AUC ↑ 53% once every other day) and
darunavir Cmin ↑ 68% increased monitoring for rifabutin
related adverse events is warranted
darunavir Cmax ↑ 39%
** in patients receiving the
sum of active moieties of rifabutin (parent
combination with PREZISTA
drug + 25-O-desacetyl metabolite)
co-administered with ritonavir. In
case of safety issues, a further
The interaction trial showed a
increase of the dosing interval for
comparable daily systemic exposure for
rifabutin and/or monitoring of
rifabutin between treatment at 300 mg
rifabutin levels should be
once daily alone and 150 mg once every
considered.
other day in combination with
Consideration should be given to
PREZISTA/ritonavir (600/100 mg twice
official guidance on the
daily) with an about 10-fold increase in
appropriate treatment of
the daily exposure to the active
tuberculosis in HIV infected
metabolite 25-O-desacetylrifabutin.
patients.
Furthermore, AUC of the sum of active
Based upon the safety profile of
moieties of rifabutin (parent drug
PREZISTA/ritonavir, the increase
+ 25-O-desacetyl metabolite) was
in darunavir exposure in the
increased 1.6-fold, while Cmax remained presence of rifabutin does not
comparable. warrant a dose adjustment for
Data on comparison with a 150 mg once PREZISTA/ritonavir.
daily reference dose is lacking. Based on pharmacokinetic
modeling, this dosage reduction of
(Rifabutin is an inducer and substrate of 75% is also applicable if patients
CYP3A.) An increase of systemic receive rifabutin at doses other
exposure to darunavir was observed when than 300 mg/day.
PREZISTA co-administered with 100 mg
ritonavir was co-administered with Co-administration of PREZISTA
rifabutin (150 mg once every other day). co-administered with cobicistat
and rifabutin is not recommended.
ANTINEOPLASTICS
Dasatinib Not studied. Boosted PREZISTA is Concentrations of these medicinal
Nilotinib expected to increase these antineoplastic products may be increased when
Vinblastine plasma concentrations. co-administered with boosted
Vincristine (CYP3A inhibition) PREZISTA resulting in the
potential for increased adverse
events usually associated with
these agents.
Caution should be exercised when
combining one of these
antineoplastic agents with boosted
PREZISTA.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dasatinib (HOS-086217) protease (HOS-085623) rifabutin (HOS-086262) vinblastine (HOS-086220) cobicistat (HOS-088111) vincristine (HOS-086219) rifapentine (HOS-116386) ritonavir (HOS-084521) nilotinib (HOS-086218)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage e88dcbfcf0dab77e559237cbcfe6847cc43133cb297e06b3715555b2ec19c33c · Zeichen 44468–51104 im Abschnitt
Wechselwirkungen · Intelence
INTELENCE 25 mg tablets INTELENCE 100 mg tablets INTELENCE 200 mg tablets · Abschnitt 4.5 · PDF-Seite 11–12
HOS-119740 · Präparat HOS-095005
11
ANTIMALARIALS
Artemether/ artemether Close monitoring of
Lumefantrine AUC ↓ 0.62 (0.48-0.80) antimalarial response is
80/480 mg, 6 doses at 0,
Cmin ↓ 0.82 (0.67-1.01) warranted when
8, 24, 36, 48, andCmax ↓ 0.72 (0.55-0.94) co-administering
60 hours dihydroartemisinin INTELENCE and
AUC ↓ 0.85 (0.75-0.97) artemether/lumefantrine as a
Cmin ↓ 0.83 (0.71-0.97) significant decrease in
Cmax ↓ 0.84 (0.71-0.99) exposure of artemether and
lumefantrine its active metabolite,
AUC ↓ 0.87 (0.77-0.98) dihydroartemisinin, may
Cmin ↔ 0.97 (0.83-1.15) result in decreased
Cmax ↔ 1.07 (0.94-1.23) antimalarial efficacy. No
etravirine dose adjustment is needed for
AUC ↔ 1.10 (1.06-1.15) INTELENCE.
Cmin ↔ 1.08 (1.04-1.14)
Cmax ↔ 1.11 (1.06-1.17)
ANTIMYCOBACTERIALS
Rifampicin Not studied. Rifampicin and rifapentine are Combination not
Rifapentine expected to decrease plasma concentrations of recommended.
etravirine.
INTELENCE should be used in combination
with a boosted PI. Rifampicin is contraindicated
in combination with boosted Pis.
Rifabutin With an associated boosted PI: The combination of
300 mg once daily No interaction study has been performed. Based INTELENCE with a boosted
on historical data, a decrease in etravirine PI and rifabutin should be
exposure may be expected whereas an increase used with caution due to the
in rifabutin exposure and especially in risk of decrease in etravirine
25-O-desacetyl-rifabutin may be expected. exposure and the risk of
increase in rifabutin and
With no associated boosted PI (out of the 25-O-desacetyl-rifabutin
recommended indication for etravirine): exposures.
rifabutin Close monitoring for
AUC ↓ 0.83 (0.75-0.94) virologic response and for
Cmin ↓ 0.76 (0.66-0.87) rifabutin related adverse
Cmax ↓ 0.90 (0.78-1.03) reactions is recommended.
25-O-desacetyl-rifabutin Please refer to the product
AUC ↓ 0.83 (0.74-0.92) information of the associated
Cmin ↓ 0.78 (0.70-0.87) boosted PI for the dose
Cmax ↓ 0.85 (0.72-1.00) adjustment of rifabutin to be
etravirine used.
AUC ↓ 0.63 (0.54-0.74)
Cmin ↓ 0.65 (0.56-0.74)
Cmax ↓ 0.63 (0.53-0.74)
BENZODIAZEPINES
Diazepam Not studied. Etravirine is expected to increase Alternatives to diazepam
plasma concentrations of diazepam. should be considered.
CORTICOSTEROIDS
Dexamethasone Not studied. Dexamethasone is expected to Systemic dexamethasone
(systemic) decrease plasma concentrations of etravirine should be used with caution
or alternatives should be
considered, particularly for
chronic use.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lumefantrine (HOS-114826) artemether (HOS-116383) rifabutin (HOS-086262) diazepam (HOS-085904) dexamethasone (HOS-084535) rifapentine (HOS-116386)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-08-13T16:37:00Z · SHA-256 b6b2c3fd3d600c0f1fd17ddc8f6c1da50bcb8b2181089113d0397c5ec46864c4 · Passage 7e0fe54c45d58654b9841db8a2c7e820382e98227be81a55de584c6f746bd26a · Zeichen 20177–24856 im Abschnitt
Gegenanzeigen · Edurant
EDURANT 25 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 3
HOS-213917 · Präparat HOS-155234
EDURANT should not be co-administered with the following medicinal products, as significant
decreases in rilpivirine plasma concentrations may occur (due to CYP3A enzyme induction or gastric
pH increase), which may result in loss of therapeutic effect of EDURANT (see section 4.5):
- the anticonvulsants carbamazepine, oxcarbazepine, phenobarbital, phenytoin
- the antimycobacterials rifampicin, rifapentine
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) carbamazepine (HOS-085618) rifapentine (HOS-116386) oxcarbazepine (HOS-110224) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-04-11T14:54:00Z · SHA-256 c02ae8018d7111133de16dc7b25339ee095e696ed781b3973764a15d8d998fed · Passage e9a36a6c900060f6535f276454fceb236e2bc6f40d5ce6e914ae327a69a2ed4d · Zeichen 93–508 im Abschnitt
Gegenanzeigen · Edurant
EDURANT 2.5 mg dispersible tablets · Abschnitt 4.3 · PDF-Seite 27
HOS-213989 · Präparat HOS-155234
EDURANT should not be co-administered with the following medicinal products, as significant
decreases in rilpivirine plasma concentrations may occur (due to CYP3A enzyme induction or gastric
pH increase), which may result in loss of therapeutic effect of EDURANT (see section 4.5):
- the anticonvulsants carbamazepine, oxcarbazepine, phenobarbital, phenytoin
- the antimycobacterials rifampicin, rifapentine
- proton pump inhibitors, such as omeprazole, esomeprazole, lansoprazole, pantoprazole,
rabeprazole
- the systemic glucocorticoid dexamethasone, except as a single dose treatment
- St John’s wort (Hypericum perforatum).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) rabeprazole (HOS-114843) esomeprazole (HOS-087944) phenobarbital (HOS-085617) carbamazepine (HOS-085618) pantoprazole (HOS-085167) dexamethasone (HOS-084535) rifapentine (HOS-116386) oxcarbazepine (HOS-110224) phenytoin (HOS-084531) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-04-11T14:54:00Z · SHA-256 c02ae8018d7111133de16dc7b25339ee095e696ed781b3973764a15d8d998fed · Passage d98981b21a5ac22277f5deb9f4fdca02f3afbd0faa096feb83283fb58697e8d1 · Zeichen 93–746 im Abschnitt
Wechselwirkungen · Edurant
EDURANT 25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-213952 · Präparat HOS-155234
(induction of CYP3A enzymes)
Rifapentine Not studied. Significant decreases Rilpivirine must not be used in
in rilpivirine plasma concentrations combination with rifapentine as
are expected. co-administration is likely to result in
loss of therapeutic effect of rilpivirine
(induction of CYP3A enzymes) (see section 4.3).
MACROLIDE ANTIBIOTICS
Clarithromycin Not studied. Increased exposure of Where possible, alternatives such as
Erythromycin rilpivirine is expected. azithromycin should be considered.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): azithromycin (HOS-088112) clarithromycin (HOS-084517) erythromycin (HOS-084514) rifapentine (HOS-116386)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-04-11T14:54:00Z · SHA-256 c02ae8018d7111133de16dc7b25339ee095e696ed781b3973764a15d8d998fed · Passage 58da341563183fcd2648a5b1a5377fef035d25f3ede0b7a4a1a44c30c2beb271 · Zeichen 10347–11125 im Abschnitt
Wechselwirkungen · Edurant
EDURANT 2.5 mg dispersible tablets · Abschnitt 4.5 · PDF-Seite 30
HOS-214005 · Präparat HOS-155234
(induction of CYP3A enzymes)
Rifapentine Not studied. Significant decreases Rilpivirine must not be used in
in rilpivirine plasma concentrations combination with rifapentine as
are expected. co-administration is likely to result in
loss of therapeutic effect of rilpivirine
(induction of CYP3A enzymes) (see section 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rifapentine (HOS-116386)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-04-11T14:54:00Z · SHA-256 c02ae8018d7111133de16dc7b25339ee095e696ed781b3973764a15d8d998fed · Passage a25cdf492d1a795ad5a448b6b1ae8b6695d0df58b2938fd78bcdf53453ee6234 · Zeichen 8944–9493 im Abschnitt
Gegenanzeigen · Eviplera
Eviplera 200 mg/25 mg/245 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 4
HOS-214348 · Präparat HOS-155326
Eviplera should not be co-administered with the following medicinal products as significant decreases
in rilpivirine plasma concentrations may occur (due to cytochrome P450 [CYP]3A enzyme induction
or gastric pH increase), which may result in loss of therapeutic effect of Eviplera:
• the anticonvulsants carbamazepine, oxcarbazepine, phenobarbital, phenytoin
• the antimycobacterials rifampicin, rifapentine
• proton pump inhibitors, such as omeprazole, esomeprazole, lansoprazole, pantoprazole,
rabeprazole
• the systemic glucocorticoid dexamethasone, except as a single dose treatment
• St. John’s wort (Hypericum perforatum)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) rabeprazole (HOS-114843) esomeprazole (HOS-087944) phenobarbital (HOS-085617) carbamazepine (HOS-085618) pantoprazole (HOS-085167) dexamethasone (HOS-084535) rifapentine (HOS-116386) oxcarbazepine (HOS-110224) phenytoin (HOS-084531) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-06-19T11:57:00Z · SHA-256 3873fd554f54608c25be65a5e155834d2d4981603221b5f24abb68e92e1af40e · Passage aa4f2e1664ff43fed53d47e187bf01139fd64995942111c422ec307cb98b6fce · Zeichen 94–760 im Abschnitt
Wechselwirkungen · Eviplera
Eviplera 200 mg/25 mg/245 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 16
HOS-214408 · Präparat HOS-155326
Tenofovir:
AUC: ↔
Cmax: ↔
Rifapentine2 Interaction not studied with any Eviplera must not be used in
components of Eviplera. combination with rifapentine as
co-administration is likely to cause
significant decreases in rilpivirine
plasma concentrations (induction
of CYP3A enzymes). This may
result in loss of therapeutic effect
of Eviplera (see section 4.3).
Macrolide antibiotics
Clarithromycin Interaction not studied with any The combination of Eviplera with
Erythromycin components of Eviplera. these macrolide antibiotics may
cause an increase in the plasma
concentrations of rilpivirine
(inhibition of CYP3A enzymes).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) clarithromycin (HOS-084517) erythromycin (HOS-084514) rifapentine (HOS-116386)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-06-19T11:57:00Z · SHA-256 3873fd554f54608c25be65a5e155834d2d4981603221b5f24abb68e92e1af40e · Passage 1d05f4254a36622807764489b9d08900cf44c5e636dbf7db51474272cd189408 · Zeichen 24001–25465 im Abschnitt
Wechselwirkungen · Zytiga
ZYTIGA 250 mg tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-125278 · Präparat HOS-096037
Strong inducers of CYP3A4 (e.g., phenytoin, carbamazepine, rifampicin, rifabutin, rifapentine,
phenobarbital, St John's wort [Hypericum perforatum]) during treatment are to be avoided, unless
there is no therapeutic alternative.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) carbamazepine (HOS-085618) rifabutin (HOS-086262) rifapentine (HOS-116386) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-10-18T14:31:00Z · SHA-256 1cd8edc18fae83339cc466c58b27be12ff13a584e8ad30419a21aea3ec2adf1f · Passage 9f070a595c2aa882f8aebe8a958bfbc9dc8f28f2bfb58eeb995e5b40ef010a1d · Zeichen 647–875 im Abschnitt
Wechselwirkungen · Zytiga
ZYTIGA 500 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 29
HOS-125311 · Präparat HOS-096037
Strong inducers of CYP3A4 (e.g., phenytoin, carbamazepine, rifampicin, rifabutin, rifapentine,
phenobarbital, St John’s wort [Hypericum perforatum]) during treatment are to be avoided, unless
there is no therapeutic alternative.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) carbamazepine (HOS-085618) rifabutin (HOS-086262) rifapentine (HOS-116386) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-10-18T14:31:00Z · SHA-256 1cd8edc18fae83339cc466c58b27be12ff13a584e8ad30419a21aea3ec2adf1f · Passage 9ad7a5917e76a6f65524501d0bd16664379e1c1b3c41d559a3bfcb48ea5dd295 · Zeichen 647–875 im Abschnitt
Wechselwirkungen · Sovaldi
Sovaldi 400 mg film-coated tablets Sovaldi 200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-129766 · Präparat HOS-096803
Medicinal products that are strong P-gp inducers in the intestine (carbamazepine, phenobarbital,
phenytoin, rifampicin and St. John’s wort) may significantly decrease sofosbuvir plasma concentration
leading to reduced therapeutic effect of Sovaldi and thus are contraindicated with Sovaldi (see
section 4.3). Medicinal products that are moderate P-gp inducers in the intestine (e.g. modafinil,
oxcarbazepine and rifapentine) may decrease sofosbuvir plasma concentration leading to reduced
therapeutic effect of Sovaldi. Co-administration with such medicinal products is not recommended
with Sovaldi (see section 4.4). Co-administration of Sovaldi with medicinal products that inhibit P-gp
and/or BCRP may increase sofosbuvir plasma concentration without increasing GS-331007 plasma
concentration, thus Sovaldi may be co-administered with P-gp and/or BCRP inhibitors. Sofosbuvir and
GS-331007 are not inhibitors of P-gp and BCRP and thus are not expected to increase exposures of
medicinal products that are substrates of these transporters.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) modafinil (HOS-090546) carbamazepine (HOS-085618) rifapentine (HOS-116386) oxcarbazepine (HOS-110224) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-08-22T14:59:00Z · SHA-256 66b8a9d8a664c3fd4fadbfdcf1cd8c6e93c3430d5e235cfa78b2847b24a28727 · Passage f0890cc7e05936c62d3d2c7cc128981d568e4b4dd49bd6df59189570ec1ad636 · Zeichen 1009–2049 im Abschnitt
Wechselwirkungen · Sovaldi
Sovaldi 400 mg film-coated tablets Sovaldi 200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10
HOS-129785 · Präparat HOS-096803
(Induction of P-gp)
Rifapentine Interaction not studied. Co-administration of Sovaldi with rifapentine is
Expected: expected to decrease the concentration of
↓ Sofosbuvir sofosbuvir, leading to reduced therapeutic effect of
↔ GS-331007 Sovaldi. Such co-administration is not
recommended (see section 4.4).
(Induction of P-gp)
HERBAL SUPPLEMENTS
St. John’s wort Interaction not studied. Sovaldi is contraindicated with St. John’s wort (see
Expected: section 4.3).
↓ Sofosbuvir
↔ GS-331007
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rifapentine (HOS-116386)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-08-22T14:59:00Z · SHA-256 66b8a9d8a664c3fd4fadbfdcf1cd8c6e93c3430d5e235cfa78b2847b24a28727 · Passage fe448b0009a0c5d8801a757f22e1860ae2915f252521d96bf8815f7b98c8652a · Zeichen 7692–8503 im Abschnitt
Wechselwirkungen · Sovaldi
Sovaldi 150 mg coated granules in sachet Sovaldi 200 mg coated granules in sachet · Abschnitt 4.5 · PDF-Seite 39
HOS-129837 · Präparat HOS-096803
Medicinal products that are strong P-gp inducers in the intestine (carbamazepine, phenobarbital,
phenytoin, rifampicin and St. John’s wort) may significantly decrease sofosbuvir plasma concentration
leading to reduced therapeutic effect of Sovaldi and thus are contraindicated with Sovaldi (see
section 4.3). Medicinal products that are moderate P-gp inducers in the intestine (e.g. modafinil,
oxcarbazepine and rifapentine) may decrease sofosbuvir plasma concentration leading to reduced
therapeutic effect of Sovaldi. Co-administration with such medicinal products is not recommended
with Sovaldi (see section 4.4). Co-administration of Sovaldi with medicinal products that inhibit P-gp
and/or BCRP may increase sofosbuvir plasma concentration without increasing GS-331007 plasma
concentration, thus Sovaldi may be co-administered with P-gp and/or BCRP inhibitors. Sofosbuvir and
GS-331007 are not inhibitors of P-gp and BCRP and thus are not expected to increase exposures of
medicinal products that are substrates of these transporters.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) modafinil (HOS-090546) carbamazepine (HOS-085618) rifapentine (HOS-116386) oxcarbazepine (HOS-110224) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-08-22T14:59:00Z · SHA-256 66b8a9d8a664c3fd4fadbfdcf1cd8c6e93c3430d5e235cfa78b2847b24a28727 · Passage f0890cc7e05936c62d3d2c7cc128981d568e4b4dd49bd6df59189570ec1ad636 · Zeichen 1009–2049 im Abschnitt
Wechselwirkungen · Sovaldi
Sovaldi 150 mg coated granules in sachet Sovaldi 200 mg coated granules in sachet · Abschnitt 4.5 · PDF-Seite 41
HOS-129854 · Präparat HOS-096803
(Induction of P-gp)
Rifapentine Interaction not studied. Co-administration of Sovaldi with rifapentine is
Expected: expected to decrease the concentration of
↓ Sofosbuvir sofosbuvir, leading to reduced therapeutic effect of
↔ GS-331007 Sovaldi. Such co-administration is not
recommended (see section 4.4).
(Induction of P-gp)
HERBAL SUPPLEMENTS
St. John’s wort Interaction not studied. Sovaldi is contraindicated with St. John’s wort (see
Expected: section 4.3).
↓ Sofosbuvir
↔ GS-331007
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rifapentine (HOS-116386)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-08-22T14:59:00Z · SHA-256 66b8a9d8a664c3fd4fadbfdcf1cd8c6e93c3430d5e235cfa78b2847b24a28727 · Passage 39c7b7d82aafb5c484344a021957c9db9dbb02c6edb3abfbecfea6ec43f376d6 · Zeichen 7849–8707 im Abschnitt
Wechselwirkungen · Lynparza
Lynparza 100 mg film-coated tablets Lynparza 150 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10
HOS-130507 · Präparat HOS-096931
A clinical study to evaluate the impact of rifampicin, a known CYP3A inducer, has shown that
co-administration with olaparib decreased olaparib mean Cmax by 71% (90% CI: 76-67%) and mean
AUC by 87% (90% CI: 89-84%). Therefore, known strong inducers of this isozyme (e.g. phenytoin,
rifampicin, rifapentine, carbamazepine, nevirapine, phenobarbital and St John’s Wort) are not
recommended with Lynparza, as it is possible that the efficacy of Lynparza could be substantially
reduced. The magnitude of the effect of moderate to strong inducers (e.g. efavirenz, rifabutin) on
olaparib exposure is not established, therefore the co-administration of Lynparza with these medicinal
products is also not recommended (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) carbamazepine (HOS-085618) rifabutin (HOS-086262) rifapentine (HOS-116386) efavirenz (HOS-087947) nevirapine (HOS-088064) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-02-19T16:20:00Z · SHA-256 04cb6a8e4fff66099a345e60858378068000de050b0e7fedaddb3d5347849598 · Passage 378c01d02895ad3c39b6f8e99161152c168de2c24f7ca49006ab5a9b1b98aca6 · Zeichen 1816–2543 im Abschnitt
Wechselwirkungen · Harvoni
Harvoni 90 mg/400 mg film-coated tablets Harvoni 45 mg/200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 11–12
HOS-132222 · Präparat HOS-097208
11
Medicinal product by Effects on medicinal Recommendation concerning co-administration
therapeutic areas product levels. with Harvoni
Mean ratio (90%
confidence interval) for
AUC, Cmax, Cmina, b
Rifapentine Interaction not studied. Co-administration of Harvoni with rifapentine is
Expected: expected to decrease the concentration of ledipasvir
↓ Ledipasvir and sofosbuvir, leading to reduced therapeutic effect
↓ Sofosbuvir of Harvoni. Such co-administration is not
↔ GS-331007 recommended.
(Induction of P-gp)
SEDATIVES/HYPNOTICS
Midazolam (2.5 mg single Observed: No dose adjustment of Harvoni or midazolam is
dose)/ ledipasvir (90 mg Midazolam required.
single dose) ↔ Cmax 1.07 (1.00, 1.14)
↔ AUC 0.99 (0.95, 1.04)
(Inhibition of CYP3A)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rifapentine (HOS-116386) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-11-10T14:39:00Z · SHA-256 5d503d87078c6a22bb188ba98b9837581fe648589d1f57d0325892e2bbaabbb1 · Passage 9b5e4be36a78e390998f4d139dc539b2e38b7cbe1cb34cf5e0123da04cf8a54f · Zeichen 12736–13959 im Abschnitt
Wechselwirkungen · Harvoni
Harvoni 33.75 mg/150 mg coated granules in sachet Harvoni 45 mg/200 mg coated granules in sachet · Abschnitt 4.5 · PDF-Seite 50
HOS-132330 · Präparat HOS-097208
(Induction of P-gp)
Rifapentine Interaction not studied. Co-administration of Harvoni with rifapentine is
Expected: expected to decrease the concentration of ledipasvir
↓ Ledipasvir and sofosbuvir, leading to reduced therapeutic effect
↓ Sofosbuvir of Harvoni. Such co-administration is not
↔ GS-331007 recommended.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rifapentine (HOS-116386)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-11-10T14:39:00Z · SHA-256 5d503d87078c6a22bb188ba98b9837581fe648589d1f57d0325892e2bbaabbb1 · Passage af937eba2e73b8250403723cfd2201f4801b2d88ac971042e29b11110eb021a8 · Zeichen 13107–13642 im Abschnitt
Wechselwirkungen · Darunavir Viatris (previously Darunavir Mylan)
Darunavir Viatris 75 mg film-coated tablets Darunavir Viatris 150 mg film-coated tablets Darunavir Viatris 300 mg film-coated tablets Darunavir Viatris 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 15–16
HOS-134497 · Präparat HOS-097580
15
INTERACTIONS AND DOSE RECOMMENDATIONS WITH OTHER MEDICINAL PRODUCTS
Medicinal products by Interaction Geometric mean change Recommendations concerning co-
therapeutic areas (%) administration
ANTIGOUT MEDICINES
Colchicine Not studied. Concomitant use of A reduction in colchicine dosage or
colchicine and darunavir co- an interruption of colchicine
administered with low dose ritonavir treatment is recommended in
may increase the exposure to patients with normal renal or
colchicine. hepatic function if treatment with
(CYP3A and/ or P-gp inhibition) darunavir co-administered with low
dose ritonavir is required. For
patients with renal or hepatic
impairment colchicine with
darunavir co-administered with low
dose ritonavir is contraindicated
(see sections 4.3 and 4.4).
ANTIMALARIALS
Artemether/Lumefantrine artemether AUC ↓ 16% The combination of darunavir and
80/480 mg, 6 doses at 0, 8, artemether Cmin ↔ artemether/lumefantrine can be used
24, 36, 48, and 60 hours artemether Cmax ↓ 18% without dose adjustments; however,
dihydroartemisinin AUC ↓ 18% due to the increase in lumefantrine
dihydroartemisinin Cmin ↔ exposure, the combination should
dihydroartemisinin Cmax ↓ 18% be used with caution.
lumefantrine AUC ↑ 175%
lumefantrine Cmin ↑ 126%
lumefantrine Cmax ↑ 65%
darunavir AUC ↔
darunavir Cmin ↓ 13%
darunavir Cmax ↔
ANTIMYCOBACTERIALS
Rifampicin Not studied. Rifapentine and rifampicin The combination of rifapentine and
Rifapentine are strong CYP3A inducers and have darunavir with concomitant low
been shown to cause profound dose ritonavir is not recommended.
decreases in concentrations of other
protease inhibitors, which can result in The combination of rifampicin and
virological failure and resistance darunavir with concomitant low
development (CYP450 enzyme dose ritonavir is contraindicated
induction). During attempts to (see section 4.3).
overcome the decreased exposure by
increasing the dose of other protease
inhibitors with low dose ritonavir, a
high frequency of liver reactions was
seen with rifampicin.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lumefantrine (HOS-114826) artemether (HOS-116383) protease (HOS-085623) colchicine (HOS-086147) rifapentine (HOS-116386) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T12:32:00Z · SHA-256 50f4771a683f17214737463c6df88a158b1e699bbb9916413602e547e369e804 · Passage 0ad9c8e97f03c4dbd0047b7a20b29278312211c101dacfc476c401ad8aa9174c · Zeichen 34084–37581 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.